Arthur Allen, Gregory Piazza, Margaret Fang/LinkedIn
Sep 12, 2025, 15:44
Long-Term Apixaban Use for Provoked VTE: Focus on HI-PRO Trial by Arthur Allen, Margaret Fang and Gregory Piazza
Anticoagulation Forum shared on LinkedIn:
”Join us for our free October webinar: Emerging Evidence: Long-term oral anticoagulation following provoked VTE? A focus on the HI-PRO Trial
Tuesday, October 7, 2025 | 12:00 PM ET
Join us as expert faculty review findings from the recent HI-PRO Trial on the use of apixaban for extended treatment of provoked venous thromboembolism (VTE).
What you’ll learn:
- Key insights from trial design and results
- Clinical implications for real-world practice
- Patient selection considerations for extended therapy
Faculty:
Arthur Allen, PharmD, CACP – Salt Lake City Va Health Care System
Margaret Fang, MD, MPH – University of California, San Francisco
Gregory Piazza, MD, MS – Brigham and Women’s Hospital”
Register here.
Stay informed on all webinars and seminars in the field of thrombosis with Hemostasis Today.
-
Jun 9, 2026, 17:55Can We Prevent Postpartum Blood Clots without Putting Most Women on Heparin? – RPTH Journal
-
Jun 9, 2026, 17:54Lucky Oseghale Oloboh: Health Is Power, Health Is Personal, and Health Is Our First Responsibility in Life’s Journey on Mother Earth
-
Jun 9, 2026, 17:53Ajay Samkaria: How ABO Subgroups Directly Impact Transfusion Safety
-
Jun 9, 2026, 17:51Alejandro González Veliz: Most Reported Aspirin Allergies Are Not True Hypersensitivity
-
Jun 9, 2026, 17:50Mary Cushman: It’s Time to Apply to Be on an ISTH SSC
-
Jun 9, 2026, 15:56Wolfgang Miesbach: A New Genetic Perspective on the Worldwide Burden of von Willebrand Disease
-
Jun 9, 2026, 15:34Shanon Marie Corsino: Nationwide Insights into Cancer-Associated Thrombosis in Filipino Patients
-
Jun 9, 2026, 15:20Murtuza Ali: Types of Blood Transfusions – A Quick Clinical Guide
-
Jun 9, 2026, 15:18Mital Jhaveri: TRACK Trial Findings Highlight the Unique Challenges of Advanced CKD